CLAIMS

We claim:

1. A crystalline form of 1,1,1,3,3,3-Hexafluoropropan-2-yl (S)-1-(pyridazin-3-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate.
2. The crystalline form according to claim 1, wherein the crystalline form is 1,1,1,3,3,3-Hexafluoropropan-2-yl (S)-1-(pyridazin-3-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate form 1 is characterized by having an XRPD obtained using $CuK_{\alpha 1}$ radiation (λ=1.5406 Å) showing peaks at the following 2Θ-angles: 10.81°, 16.54°.16.76°, and 19.21°.
3. The crystalline form according to claim 1, wherein the crystalline form is 1,1,1,3,3,3-Hexafluoropropan-2-yl (S)-1-(pyridazin-3-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate form 3 is characterized by having an XRPD obtained using CuKα1 radiation (λ=1.5406 Å) showing peaks at the following 2Θ-angles: 6.61°, 9.16°, 13.09°, and 14.32°.
4. A solid dosage form comprising a crystalline form according to any one of claims 1-3, and one or more pharmaceutically acceptable carriers or diluents.
5. The solid dosage form according to claim 4, wherein the solid dosage form is selected form capsules, tablets, dragées, pills, lozenges, powders and granules.
6. The solid dosage form according to claim 4, wherein the solid dosage form is a tablet.
7. The solid dosage form according to any one of claims 4-6, wherein the dosage form comprises the crystalline form of 1,1,1,3,3,3-Hexafluoropropan-2-yl (S)-1-(pyridazin-3-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate in an amount from about 0.1 to 200 mg.
8. The solid dosage form according to any one of claims 4-6, wherein the dosage form comprises the crystalline form of 1,1,1,3,3,3-Hexafluoropropan-2-yl (S)-(pyridazin-3-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate in an amount from about 1 to 40 mg.
9. The solid dosage form according to any one of claims 4-6, wherein the dosage form comprises the crystalline form of 1,1,1,3,3,3-Hexafluoropropan-2-yl (S)-(pyridazin-3-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate in an amount from about 1 to 30 mg.
10. The solid dosage form according to any one of claims 4-6, wherein the dosage form comprises the crystalline form of 1,1,1,3,3,3-Hexafluoropropan-2-yl (S)-(pyridazin-3-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate in an amount from about 1 to 20 mg.

11. The solid dosage form according to any one of claims 4-10, wherein the crystalline form is 1,1,1,3,3,3-Hexafluoropropan-2-yl (S)-(pyridazin-3-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate form 1.
12. The solid dosage form according to any one of claims 4-10, wherein the crystalline form is 1,1,1,3,3,3-Hexafluoropropan-2-yl (S)-(pyridazin-3-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate form 3.
13. The crystalline form of 1,1,1,3,3,3-Hexafluoropropan-2-yl (S)-(pyridazin-3-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate according to any of claims 1-3 or a solid dosage form according to anyone of claims 4-12, for use in the treatment of a disease or disorder selected from atopic dermatitis, bladder dysfunction associated with multiple sclerosis, cardiovascular disease, contact dermatitis, cystic fibrosis, dermatomyositis, eczema, endometriosis, enteritis, fibromyalgia, inflammatory bowel disease, interstitial cystitis, irritable bowel syndrome, ischemia, labor, abdominal pain, abdominal pain associated with irritable bowel syndrome, acute pain, back pain, cancer pain, chest pain, functional chest pain, joint pain, menstrual pain, metabolic disorders, musculoskeletal diseases, peripheral neuropathy, migraine, visceral hypersensitivity, osteoarthritis, pancreatitis, pharyngitis, post mastectomy pain syndrome, trigeminal neuralgia, post-operative pain, post-traumatic stress disorder, renal ischemia, rheumatoid arthritis, skeletal muscle contusion, skin diseases, sunburn, systemic lupus erythematosus, toothache, vasoocclusive painful crises in sickle cell disease, and visceral pain.
14. Use of a crystalline form of 1,1,1,3,3,3-Hexafluoropropan-2-yl (S)-1-(pyridazin-3-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate according to any of claims 1-3 or a solid dosage form according to anyone of claims 4-12, in the manufacture of a medicament for the treatment of disease or a disorder selected from atopic dermatitis, bladder dysfunction associated with multiple sclerosis, cardiovascular disease, contact dermatitis, cystic fibrosis, dermatomyositis, eczema, endometriosis, enteritis, fibromyalgia, inflammatory bowel disease, interstitial cystitis, irritable bowel syndrome, ischemia, labor, abdominal pain, abdominal pain associated with irritable bowel syndrome, acute pain, back pain, cancer pain, chest pain, functional chest pain, joint pain, menstrual pain, metabolic disorders, musculoskeletal diseases, peripheral neuropathy, migraine, visceral hypersensitivity, osteoarthritis, pancreatitis, pharyngitis, post mastectomy pain syndrome, trigeminal neuralgia, post-operative pain, post-traumatic stress disorder, renal ischemia, rheumatoid arthritis, skeletal

muscle contusion, skin diseases, sunburn, systemic lupus erythematosus, toothache, vasoocclusive painful crises in sickle cell disease, and visceral pain.